InnoPharmax Inkomsten in het verleden
Verleden criteriumcontroles 0/6
InnoPharmax's earnings have been declining at an average annual rate of -3.6%, while the Pharmaceuticals industry saw earnings growing at 8.8% annually. Revenues have been declining at an average rate of 21.2% per year.
Belangrijke informatie
-3.6%
Groei van de winst
2.6%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 18.5% |
| Inkomstengroei | -21.2% |
| Rendement op eigen vermogen | -19.3% |
| Nettomarge | -241.5% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe InnoPharmax geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 35 | -84 | 29 | 71 |
| 31 Mar 24 | 40 | -77 | 26 | 65 |
| 31 Dec 23 | 46 | -71 | 23 | 59 |
| 30 Sep 23 | 48 | -77 | 23 | 60 |
| 30 Jun 23 | 49 | -84 | 23 | 61 |
| 31 Mar 23 | 39 | -94 | 22 | 66 |
| 31 Dec 22 | 29 | -103 | 21 | 72 |
| 30 Sep 22 | 32 | -102 | 22 | 70 |
| 30 Jun 22 | 34 | -101 | 23 | 68 |
| 31 Mar 22 | 41 | -97 | 22 | 64 |
| 31 Dec 21 | 48 | -93 | 22 | 60 |
| 30 Sep 21 | 79 | -77 | 22 | 60 |
| 30 Jun 21 | 110 | -62 | 23 | 60 |
| 31 Mar 21 | 123 | -53 | 24 | 61 |
| 31 Dec 20 | 137 | -44 | 26 | 62 |
| 30 Sep 20 | 128 | -54 | 26 | 66 |
| 30 Jun 20 | 119 | -63 | 26 | 70 |
| 31 Mar 20 | 102 | -76 | 24 | 78 |
| 31 Dec 19 | 85 | -88 | 23 | 86 |
| 30 Sep 19 | 66 | -88 | 23 | 87 |
| 30 Jun 19 | 46 | -88 | 23 | 87 |
| 31 Mar 19 | 51 | -87 | 26 | 84 |
| 31 Dec 18 | 56 | -86 | 28 | 80 |
| 30 Sep 18 | 49 | -105 | 33 | 85 |
| 30 Jun 18 | 39 | -124 | 37 | 91 |
| 31 Mar 18 | 41 | -143 | 41 | 109 |
| 31 Dec 17 | 44 | -162 | 45 | 127 |
| 30 Sep 17 | 58 | -44 | 44 | 128 |
| 30 Jun 17 | 59 | -65 | 51 | 148 |
| 31 Mar 17 | 52 | -57 | 54 | 136 |
| 31 Dec 16 | 46 | -49 | 56 | 124 |
| 30 Sep 16 | 37 | -160 | 56 | 126 |
| 30 Jun 16 | 45 | -134 | 49 | 108 |
| 31 Mar 16 | 45 | -130 | 47 | 107 |
| 31 Dec 15 | 44 | -126 | 46 | 106 |
| 30 Sep 15 | 45 | -123 | 48 | 103 |
| 30 Jun 15 | 46 | -121 | 51 | 100 |
| 31 Mar 15 | 78 | -89 | 51 | 103 |
| 31 Dec 14 | 109 | -58 | 51 | 105 |
| 30 Sep 14 | 104 | -65 | 49 | 112 |
| 30 Jun 14 | 100 | -72 | 46 | 119 |
| 31 Mar 14 | 67 | -106 | 45 | 120 |
| 31 Dec 13 | 34 | -141 | 43 | 122 |
Kwaliteitswinsten: 4172 is currently unprofitable.
Groeiende winstmarge: 4172 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 4172 is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.
Versnelling van de groei: Unable to compare 4172's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 4172 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.6%).
Rendement op eigen vermogen
Hoge ROE: 4172 has a negative Return on Equity (-19.26%), as it is currently unprofitable.